Analytical aspects of molecular Alzheimer's disease biomarkers.
about
Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research ResultsAlzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele.Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics.CSF biomarker variability in the Alzheimer's Association quality control program.Metabolic profiling of Alzheimer's disease brainsPittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.Potential sources of interference on Abeta immunoassays in biological samplesNovel fluorescent microarray platforms: a case study in neurodegenerative disorders.Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.Roadblocks for integration of novel biomarker concepts into clinical routine: the peptoid approach.Transferring cut-off values between assays for cerebrospinal fluid Alzheimer's disease biomarkers.A digital enzyme-linked immunosorbent assay for ultrasensitive measurement of amyloid-β 1-42 peptide in human plasma with utility for studies of Alzheimer's disease therapeutics.Early diagnosis of Alzheimer's disease using infrared spectroscopy of isolated blood samples followed by multivariate analyses.
P2860
Q27345258-300D7ADE-70C0-4FB6-BF8C-9C54F00F0171Q30996799-A0322AF5-F570-4418-840C-6538455F5DB1Q33363912-894629DF-2F84-4E59-8FBA-E28532987881Q33769278-1516F058-B7E0-4B3A-81F7-C0041C554EE3Q36999855-1AFDBD1C-CDFA-4E52-B797-C5A33C5E2795Q37072582-E2B86A96-576D-44F6-AE75-4C1F1D010C73Q37198556-CCB59F43-1B32-4DB0-AE2E-5DE146EC9D9EQ38037154-1F68E16B-6414-4EB3-8033-8652C914511DQ38053449-8A97A1A8-9C34-4006-9D51-5773A6C443A7Q38154931-5ED83628-63D1-4DE9-AB02-95E4365B73CAQ38210117-E28D19BB-A992-409B-8BC6-F36E6CB65789Q38230387-2763FC5C-9A0F-4881-B0E0-98CFBFA2EBB6Q40410669-828B2681-C300-4517-80FD-B9DC28082191Q40428596-4E6096DC-D6F9-48BD-8DBF-86056E42F172Q47883557-0FF30E62-7E53-4557-A303-651B1E1157DA
P2860
Analytical aspects of molecular Alzheimer's disease biomarkers.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Analytical aspects of molecular Alzheimer's disease biomarkers.
@en
type
label
Analytical aspects of molecular Alzheimer's disease biomarkers.
@en
prefLabel
Analytical aspects of molecular Alzheimer's disease biomarkers.
@en
P2093
P2860
P356
P1476
Analytical aspects of molecular Alzheimer's disease biomarkers.
@en
P2093
Hugo Vanderstichele
Leslie M Shaw
Ulf Andreasson
P2860
P304
P356
10.2217/BMM.12.44
P577
2012-08-01T00:00:00Z